Lahore: Citi Pharma Ltd. revealed their financial results for the fiscal year ending June 30, 2024, announcing a final cash dividend of Rs. 3.25 per share. This declaration came after the Board of Directors’ meeting on October 1, 2024, where the financial statements were approved and recommended for the fiscal year.
According to information available from the Pakistan Stock Exchange (PSX), the company reported significant financial performance with a gross profit of 1.59 billion Rupees for the year, slightly up from 1.51 billion Rupees the previous year. Operating profit was also robust at 1.21 billion Rupees, while profit after income tax stood at 833.46 million Rupees, marking a noticeable increase from the previous year’s 657.98 million Rupees.
Earnings per share (EPS) for the fiscal year were reported at 3.65 Rupees. The company noted that no bonus shares were issued, and no rights shares or other corporate actions were proposed. The administrative and general expenses accounted for 204.14 million Rupees while marketing and distribution expenses tallied up to 176.41 million Rupees. The financial charges for the year included were at 299.91 million Rupees.
Citi Pharma highlighted the effective management and operations that led to these results. The Annual General Meeting is scheduled for October 28, 2024, at 11:00 AM in Lahore, with more detailed financials to be disclosed.
The company’s performance, especially in terms of net sales, which were recorded at 12.40 billion Rupees, and a significant reduction in financial charges compared to the previous fiscal year, reflects its solid footing in the market amidst challenging economic conditions.